Marit Muri Holmen

Marit Muri Holmen

Auto-generated profile, based on publicly available information

Marit Muri Holmen

Department of Breast Diagnostics, Division of Radiology and Nuclear Medicine, Oslo University Hospital, 0379 Oslo, Norway

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
VDVanessa Dumeaux
Vanessa Dumeaux
JUJosie Ursini-Siegel
Josie Ursini-Siegel
AFArnar Flatberg
Arnar Flatberg
HFHans E. Fjosne
Hans E. Fjosne
JFJan‐Ole Frantzen
Jan‐Ole Frantzen
ELEiliv Lund
Eiliv Lund
Tumor–host interactions extend beyond the local microenvironment and cancer development largely depends on the ability of malignant cells to hijack and exploit the normal physiological processes of the host. Here, we established that many genes within peripheral blood cells show differential expression when an untreated breast cancer (BC) is present, and harnessed this fact to construct a 50‐gene signature that distinguish BC patients from population‐based controls. Our results were derived from a series of large datasets within our unique population‐based Norwegian Women and Cancer cohort that allowed us to investigate the influence of medications and tumor characteristics on our blood‐based test, and were further tested in two external datasets. Our 50‐gene signature contained cytostatic signals including the specific suppression of the immune response and medications influencing transcription involved in those processes were identified as confounders. Through analysis of the biological processes differentially expressed in blood, we were able to provide a rationale as to why the systemic response of the host may be a reliable marker of BC, characterized by the underexpression of both immune‐specific pathways and “universal” cell programs driven by MYC (i.e., metabolism, growth and cell cycle). In conclusion, gene expression of peripheral blood cells is markedly perturbed by the specific presence of carcinoma in the breast and these changes simultaneously engage a number of systemic cytostatic signals emerging connections with immune escape of BC.

28 September 2017 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
VDVanessa Dumeaux
Vanessa Dumeaux
BFBjørn Fjukstad
Bjørn Fjukstad
HFHans E Fjosne
Hans E Fjosne
JFJan-Ole Frantzen
Jan-Ole Frantzen
MHMarit Muri Holmen
Marit Muri Holmen
MHMichael Hallett
Michael Hallett
Although systemic immunity is critical to the process of tumor rejection, cancer research has largely focused on immune cells in the tumor microenvironment. To understand molecular changes in the patient systemic response (SR) to the presence of BC, we profiled RNA in blood and matched tumor from 173 patients. We designed a system (MIxT, Matched Interactions Across Tissues) to systematically explore and link molecular processes expressed in each tissue. MIxT confirmed that processes active in the patient SR are especially relevant to BC immunogenicity. The nature of interactions across tissues (i.e. which biological processes are associated and their patterns of expression) varies highly with tumor subtype. For example, aspects of the immune SR are underexpressed proportionally to the level of expression of defined molecular processes specific to basal tumors. The catalog of subtype-specific interactions across tissues from BC patients provides promising new ways to tackle or monitor the disease by exploiting the patient SR. We present a novel system (MIxT) to identify genes and pathways in the primary tumor that are tightly linked to genes and pathways in the patient systemic response (SR). These results suggest new ways to tackle and monitor the disease by looking outside the tumor and exploiting the patient SR.

27 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Siri Helene Bertelsen BrandalSiri Helene Bertelsen Brandal
Siri Helene Bertelsen Brandal
TMTorgeir Mo
Torgeir Mo
AFAnne Fangberget
Anne Fangberget
LNLine Brennhaug Nilsen
Line Brennhaug Nilsen
OGOliver Marcel Geier
Oliver Marcel Geier
TSTherese Seierstad
Therese Seierstad
Objectives: To explore if MRI can monitor treatment and predict outcome in patients with human epidermal growth factor 2 (HER2)-negative breast cancer receiving neoadjuvant chemotherapy (NACT) with or without bevacizumab. Methods: Multiparametric MRI was performed at baseline and after 12 and 25 weeks of NACT. MRI assessment included tumour size, apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI), and signal intensity–time curves and vascular volume transfer constant (KTRANS) from dynamic contrast-enhanced MRI (DCE). The reference standards were pathological complete response (pCR) at the time of surgery, and 10-year recurrence-free survival. Receiver operating characteristics analyses were performed to assess the predictive value of the MRI parameters. MRI findings and outcomes were compared between the treatment groups. Results: Seventy women were included from November 2008 to July 2012, with a median age of 49.5 years and median tumour diameter of 47 mm. Fourteen patients (20.0%) achieved pCR, while eleven (15.7%) had recurrence during the 10-year follow-up. The treatment significantly reduced tumour size, increased ADC, decreased KTRANS, and shifted the signal intensity–time curves towards more benign shapes. The DCE parameters changed significantly more in the bevacizumab group. In the bevacizumab group, baseline KTRANS predicted pCR (Area under curve (AUC) = 0.73), but the difference in pCR-rates between the treatment groups was not significant (p = 0.07). Only tumour size and shrinkage at 12 weeks predicted pCR (AUC = 0.71–0.85) regardless of size measuring method. No MRI parameters predicted survival. Conclusions: All MRI parameters reflected treatment response, but no parameter predicted survival or benefit from adding bevacizumab to chemotherapy.